Trial Profile
A Single Centre, Randomised, Double Blind, Phase 1 Study of the Safety, Tolerability, and Immunogenicity of an Influenza Vaccine Candidate (FLU-v).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs FLU-v (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- 17 May 2012 Results were published in the online May edition of Vaccine, according to a SEEK media release.
- 08 Dec 2010 Results, from 48 patients, have been presented at the World Influenza Congress in Amsterdam, according to a SEEK media release.
- 14 Oct 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.